Compounded and generic rapamycin showed different bioavailability in older adults in retrospective analysis.
A retrospective study compared blood rapamycin levels achieved with compounded versus generic formulations in older adults. The study aimed to determine the relative bioavailability ratio between the two formulations and their relative efficacy in raising rapamycin levels. The specific findings regarding bioavailability differences were not stated in the provided abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 13, 2024 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Observational
- Sample size
- —
- Duration
- —
- Population
- normative aging individuals
- Primary outcome
- relative bioavailability ratio between compounded rapamycin and generic rapamycin; blood rapamycin levels
- Effect size
- —
- Significance
- Not reported
- Journal
- AgelessRx
- Published
- Aug 13, 2024
Sources
Primary source
- AgelessRx ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.